Supplementary Tables 1-6 from ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy

Supplementary Table S1: X-ray crystallography data processing and structure refinement statistics Supplementary Table S2: BRAF and RAS mutational status of cell lines used in the study Supplementary Table: S3: Cellular IC50 (nM) of parental and ERKi-resistant lines to ERK inhibitors Supplementary Table S4: Mutations found in ERKi- resistant lines. Supplementary Table-S5- Copy number (log2 ratio) in ERKi-R lines compare to parental cell lines. Supplementary Table S6: Gene expression (RPKM) in parental and ERKi-R cells